NCT05724563

Domvanalimab and Zimberelimab in Advanced Liver Cancers

Phase II Basket Trial of Domvanalimab (AB154) and Zimberelimab (AB122) in Advanced Hepatobiliary Cancers

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: University of Texas Southwestern Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about advanced liver and bile duct cancers. The main question it aims to answer is: If the combination of Domvanalimab and Zimberelimab are effective in treating advanced hepatobiliary cancers that have failed prior treatment.

Conditions

• Hepatobiliary Cancer
• Liver Cancer
• Cholangiocarcinoma
• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Zimberelimab	Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
DRUG	Domvanalimab	Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.

Timeline

• Start date: 2023-06-01
• Primary completion: 2026-07-01
• Completion: 2027-06-01
• First posted: 2023-02-13
• Last updated: 2025-05-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study